title: Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.
abstract: Immunoglobulins (Igs) that bind amyloid beta peptide (Abeta) are under clinical trials for immunotherapy of Alzheimer disease (AD). We have identified IgMs and recombinant Ig fragments that hydrolyze Abeta. Hydrolysis of peripheral Abeta by the IgMs may induce increased Abeta release from the brain. The catalytic IgMs are increased in AD patients, presumably reflecting a protective autoimmune response. Reduced Abeta aggregation and neurotoxicity attributable to the catalytic function were evident. These findings provide a foundation for development of catalytic Igs for AD immunotherapy.
authors.affiliation: Chemical Immunology Research Center, University of Texas Houston Medical School, Houston, TX 77030, USA.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Taguchi
authors.forename: Stephanie
authors.initials: S
authors.lastname: Planque
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Nishiyama
authors.forename: Paul
authors.initials: P
authors.lastname: Szabo
authors.forename: Marc E
authors.initials: ME
authors.lastname: Weksler
authors.forename: Robert P
authors.initials: RP
authors.lastname: Friedland
authors.forename: Sudhir
authors.initials: S
authors.lastname: Paul
mesh_terms: D000544:Alzheimer Disease / Q000276:immunology* / Q000378:metabolism / Q000628:therapy; D016229:Amyloid beta-Peptides / Q000276:immunology / Q000378:metabolism*; D017151:Antibodies, Catalytic / Q000276:immunology / Q000378:metabolism* / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D006868:Hydrolysis; D007075:Immunoglobulin M / Q000276:immunology / Q000378:metabolism*; D007167:Immunotherapy
chemical_list: D016229:Amyloid beta-Peptides; D017151:Antibodies, Catalytic; D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D007075:Immunoglobulin M